RT @BOUTRON1: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by @CovidNma in our Coch…

Ahora quien pagará

Conoce si los medicamentos que bloquean la #Interleucina6 pueden funcionar para combatir #COVID19, en el siguiente artículo de @cochranecollab https://t.co/mlX1Kj5pgE https://t.co/MpUUoqjOyx

RT @BOUTRON1: The COVID-NMA initiative @CovidNma is very proud of the Cochrane review published today on IL-6 blocking agents for COVID-19…

RT @BOUTRON1: The COVID-NMA initiative @CovidNma is very proud of the Cochrane review published today on IL-6 blocking agents for COVID-19…

RT @BOUTRON1: The COVID-NMA initiative @CovidNma is very proud of the Cochrane review published today on IL-6 blocking agents for COVID-19…

RT @BOUTRON1: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by @CovidNma in our Coch…

RT @BOUTRON1: The COVID-NMA initiative @CovidNma is very proud of the Cochrane review published today on IL-6 blocking agents for COVID-19…

The COVID-NMA initiative @CovidNma is very proud of the Cochrane review published today on IL-6 blocking agents for COVID-19 published in the @CochraneLibrary https://t.co/cMfqYPrt1P https://t.co/Dj2X2gc0qA

Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by @CovidNma in our Cochrane Review on Interleukin-6 blocking agents, now published in the @CochraneLibrary https://t.co/cMfqYPrt1P

Revision Cochrane de anti-IL6 (Tocilizumab), 10 estudios, casi 7,000 px, a favor de indicarlo por reducción de mortalidad a 28 días. https://t.co/rpXfB1o8jh

4/ citas https://t.co/CIkN36oQUo https://t.co/LLY9cMFtAi Creo que es hora de replantear recomendaciones MSAL.....

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…

Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on Interleukin-6 blocking agents, now published in the @CochraneLibrary: https://t.co/dEFmwA1Msa https://t.co/O2gYy4a16J

RT @CochraneFrance: Revue Cochrane publiée grâce à @CovidNma Interleukin‐6 blocking agents for treating COVID‐19: a living systematic rev…

New article: Interleukin-6 blocking agents for treating COVID-19: a living systematic review https://t.co/0qA4QHjZ6c #coronavirus #COVID19 #2019ncov https://t.co/YvfTfZgXan

RT @rmchavin: 3-18-2021: Lina Ghosn excludes 90% of the pro-Actemra studies and places heavy emphasis on the few anti-Actemra studies. De…

3-18-2021: Lina Ghosn excludes 90% of the pro-Actemra studies and places heavy emphasis on the few anti-Actemra studies. Despite this, her COVID-19 meta-analysis concludes, "tocilizumab reduces all-cause mortality and serious adverse events at Day 28" ht

RT @epistemonikos: A new #Living Systematic Review📰 sees the light thanks to collaborative work and our #L·OVE Platform💚💪 Congratulations t…

Can medicines that block interleukin-6 (a protein involved in immune responses) treat COVID-19? | Cochrane https://t.co/iLjLTolVPg

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @tlassers: In RECOVERY? @CochraneLibrary review of IL-6 blocking agents (tocilizumab) for #COVID https://t.co/PTRuYV7vXj

RT @CiimetF: Tocilizumab. Revisión Cochrane concluye evidencia de q reduce la mortalidad. https://t.co/TJjIxvZJdE

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review https://t.co/WeUEyBiSuh

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @joseluis_pa: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library https…

@LuisCLCorreia diminuí mortalidade, mas sem melhora clínica no D28? Entendi não. Dados enviesados para melhora clínica? Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review https://t.co/WeUEyBiSuh

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

RT @epistemonikos: A new #Living Systematic Review📰 sees the light thanks to collaborative work and our #L·OVE Platform💚💪 Congratulations t…

RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…

Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡Felicitaciones a nuestros Drs. @CamiAvilaO, @radagabriel y todo el equipo de autores! #Interleukin6 blocking agents for #COVID19 https://t.

A new #Living Systematic Review📰 sees the light thanks to collaborative work and our #L·OVE Platform💚💪 Congratulations to our Drs @CamiAvilaO, @radagabriel and all the authors! #Interleukin6 blocking agents for #COVID19 👇 https://t.co/wUBnsysWcW https://t

RT @tlassers: In RECOVERY? @CochraneLibrary review of IL-6 blocking agents (tocilizumab) for #COVID https://t.co/PTRuYV7vXj

RT @CochraneIreland: We are very happy to be a part of this @cochranecollab review w/ @CovidNma. The results show that treating #COVID19 wi…

RT @CochraneIreland: We are very happy to be a part of this @cochranecollab review w/ @CovidNma. The results show that treating #COVID19 wi…

RT @EvidSynIRL: Great to see this published @decdevane in @CochraneLibrary for treatment of #COVID19 which shows that #tocilizumab reduced…

We are very happy to be a part of this @cochranecollab review w/ @CovidNma. The results show that treating #COVID19 with #tocilizumab (an IL-6 blocker)⬇️ the # of people who die within 28d of trt, & probably has fewer unwanted effects @n_gnursing @Evid

Tocilizumab. Revisión Cochrane concluye evidencia de q reduce la mortalidad. https://t.co/TJjIxvZJdE

RT @CochraneLibrary: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic rev…

RT @tlassers: In RECOVERY? @CochraneLibrary review of IL-6 blocking agents (tocilizumab) for #COVID https://t.co/PTRuYV7vXj

RT @EvidSynIRL: Great to see this published @decdevane in @CochraneLibrary for treatment of #COVID19 which shows that #tocilizumab reduced…

RT @CochraneLibrary: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic rev…

RT @CochraneColomb: Cochrane publica hoy la "revisión sistemática viva" de los bloqueadores de inteleuquina 6 para el tratamiento de COVID-…

RT @CochraneColomb: Cochrane publica hoy la "revisión sistemática viva" de los bloqueadores de inteleuquina 6 para el tratamiento de COVID-…

RT @tlassers: In RECOVERY? @CochraneLibrary review of IL-6 blocking agents (tocilizumab) for #COVID https://t.co/PTRuYV7vXj

RT @CochraneLibrary: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic rev…

Fantastic to see such useful research published, well done to everyone involved! 👏

Cochrane publica hoy la "revisión sistemática viva" de los bloqueadores de inteleuquina 6 para el tratamiento de COVID-19 Conclusión principal: "Tocilizumab redujo el número de muertes, por cualquier causa, a los 28 días (confianza baja a moderada)" htt

RT @EvidSynIRL: Great to see this published @decdevane in @CochraneLibrary for treatment of #COVID19 which shows that #tocilizumab reduced…

Revue Cochrane publiée grâce à @CovidNma Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (Ghosn L et al, Cochrane Library) https://t.co/F6NlgqezYC @cochranecollab @CochraneLibrary @Cochrane_DE @CochraneDK @CochraneChile @

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library https://t.co/jylmFx6vN7

RT @tlassers: In RECOVERY? @CochraneLibrary review of IL-6 blocking agents (tocilizumab) for #COVID https://t.co/PTRuYV7vXj

Great to see this published @decdevane in @CochraneLibrary for treatment of #COVID19 which shows that #tocilizumab reduced number of deaths. This will be updated weekly on @CovidNma platform. Another international collaborative effort 👏 @hrbireland @saol

RT @tlassers: In RECOVERY? @CochraneLibrary review of IL-6 blocking agents (tocilizumab) for #COVID https://t.co/PTRuYV7vXj

In RECOVERY? @CochraneLibrary review of IL-6 blocking agents (tocilizumab) for #COVID https://t.co/PTRuYV7vXj

RT @CochraneLibrary: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic rev…

Interleucina6

RT @CochraneLibrary: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic rev…

RT @CochraneLibrary: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic rev…

RT @CochraneLibrary: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic rev…

JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/9qGXrknq1X New living systematic review from @Cochrane_ACE looks at the evidence from 10 studies in 6896 people with COVID‐19.